Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: moelleken j. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov. EMBO Mol Med. 2016. PMID: 27742718 Free PMC article.
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Gemmy Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: moelleken j. EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895. EMBO Mol Med. 2017. PMID: 28533211 Free PMC article.
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Chui Ming GC, Tun SBB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: moelleken j. EMBO Mol Med. 2019 May;11(5):e10666. doi: 10.15252/emmm.201910666. EMBO Mol Med. 2019. PMID: 31040127 Free PMC article.
Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, Tissot AC, Tan SL, Seeber S, Schett G. Fischer JA, et al. Among authors: moelleken j. Arthritis Rheumatol. 2015 Jan;67(1):51-62. doi: 10.1002/art.38896. Arthritis Rheumatol. 2015. PMID: 25303306
Differential localization of coatomer complex isoforms within the Golgi apparatus.
Moelleken J, Malsam J, Betts MJ, Movafeghi A, Reckmann I, Meissner I, Hellwig A, Russell RB, Söllner T, Brügger B, Wieland FT. Moelleken J, et al. Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4425-30. doi: 10.1073/pnas.0611360104. Epub 2007 Mar 7. Proc Natl Acad Sci U S A. 2007. PMID: 17360540
16 results